{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:08Z","timestamp":1793459648118,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00535-025-02312-1","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:33:41Z","timestamp":1761849221000},"page":"302-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial"],"prefix":"10.1007","volume":"61","author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2312_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"key":"2312_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2312_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/hepr.14131","volume":"55","author":"Y Tahata","year":"2024","unstructured":"Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, et al. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy. Hepatol Res. 2024;55(3):319\u201332.","journal-title":"Hepatol Res"},{"key":"2312_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","volume":"13","author":"I Gentile","year":"2019","unstructured":"Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (liver network activity-LINA cohort). Hepatol Int. 2019;13:66\u201374.","journal-title":"Hepatol Int"},{"key":"2312_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40121-020-00329-y","volume":"9","author":"M Atsukawa","year":"2020","unstructured":"Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, et al. Real-world clinical application of 12-week sofosbuvir\/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 2020;9:851\u201366.","journal-title":"Infect Dis Ther"},{"key":"2312_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","volume":"167","author":"M Premkumar","year":"2024","unstructured":"Premkumar M, Dhiman RK, Duseja A, Mehtani R, Taneja S, Gupta E, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program. Gastroenterology. 2024;167:1429\u201345.","journal-title":"Gastroenterology"},{"key":"2312_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"2312_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/hepr.13739","volume":"52","author":"M Atsukawa","year":"2022","unstructured":"Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, et al. Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235\u201346.","journal-title":"Hepatol Res"},{"key":"2312_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01963-2","author":"K Kotani","year":"2023","unstructured":"Kotani K, Enomoto M, Uchida-Kobayashi S, Tamori A, Yukawa-Muto Y, Odagiri N, et al. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis. J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s00535-023-01963-2.","journal-title":"J Gastroenterol"},{"key":"2312_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/hepr.13837","volume":"53","author":"T Sano","year":"2023","unstructured":"Sano T, Amano K, Ide T, Yokoyama K, Noguchi K, Nakamura H, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir\/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26\u201334.","journal-title":"Hepatol Res"},{"key":"2312_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/hepr.13926","volume":"53","author":"Y Uchida","year":"2023","unstructured":"Uchida Y, Imai Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, et al. Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir. Hepatol Res. 2023;53:815\u201328.","journal-title":"Hepatol Res"},{"key":"2312_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","volume":"74","author":"LAP Krassenburg","year":"2021","unstructured":"Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053\u201363.","journal-title":"J Hepatol"},{"key":"2312_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2022.102697","volume":"26","author":"GH Pereira","year":"2022","unstructured":"Pereira GH, Peixoto HR, Giusti ML, Souza ML, Victor LB, Fernandes F, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Braz J Infect Dis. 2022;26:102697.","journal-title":"Braz J Infect Dis"},{"key":"2312_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00535-023-02039-x","volume":"58","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, et al. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023;58:1211\u201321.","journal-title":"J Gastroenterol"},{"key":"2312_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023;53:383\u201390.","journal-title":"Hepatol Res"},{"key":"2312_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11:165\u2013223.","journal-title":"Diabetol Int"},{"key":"2312_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2312_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. a study of 200 patients. J Hepatol. 2004;40:823\u201330.","journal-title":"J Hepatol"},{"key":"2312_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12876-021-01770-0","volume":"21","author":"S Fujiyama","year":"2021","unstructured":"Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, Hosaka T, et al. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study. BMC Gastroenterol. 2021;21:189.","journal-title":"BMC Gastroenterol"},{"key":"2312_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.29811","volume":"68","author":"LI Backus","year":"2018","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827\u201338.","journal-title":"Hepatology"},{"key":"2312_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hep.29408","volume":"69","author":"LI Backus","year":"2019","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2019;69:487\u201397.","journal-title":"Hepatology"},{"key":"2312_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/hepr.13868","volume":"53","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Sakamori R, Maesaka K, Doi A, Yamada R, Kodama T, et al. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023;53:301\u201311.","journal-title":"Hepatol Res"},{"key":"2312_CR23","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus Infection. Gastroenterology. 2018;154:2111-2121 e2118.","journal-title":"Gastroenterology"},{"issue":"1","key":"2312_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68(1):25\u201332.","journal-title":"J Hepatol"},{"key":"2312_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-1005 e1001.","journal-title":"Gastroenterology"},{"key":"2312_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","volume":"156","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology. 2019;156:446-460 e442.","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02312-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02312-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02312-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:45:59Z","timestamp":1776786359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02312-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02312-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hayato Hikita received lecture fees from Gilead Sciences, Inc. Masayuki Kurosaki received lecture fees from Gilead Sciences, Inc, AbbVie, Eisai, and AstraZeneca. Masato Nakamura received research grants and lecture fees from AbbVie GK. Ryotaro Sakamori received lecture fees from Gilead Sciences, Inc. Takeda. Takahiro Kodama received lecture fees from AbbVie GK. and Gilead Sciences, Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}